Science

Olubukola Ayodele: The results of EMBER-3 are out in NEJM

Collage photo of Olubukola Ayodele and Komal Jhaveri

Dec 15, 2024, 21:04

Olubukola Ayodele: The results of EMBER-3 are out in NEJM

A recent paper by Komal Jhaveri, Clinical Director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, published in The New England Journal of Medicine was mentioned by Olubukola Ayodele, Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, on LinkedIn:

“While we are currently in the main hall for the very much awaited presentation at SABCS24, the results of EMBER-3 are out in NEJM.

Imlunestrant and abemaciclib had significantly better PFS as compared with imlunestrant, regardless of ESR1-mutation status and combo of abemaciclib and imlumnestrant is better independent of mutations in all.

Note incidence of gd3 toxicity is almost 50% in the combination arm compared to single agent imlunestrant or fulvestrant.

What are your thoughts?

Where does this stand with patients already exposed to cdk4/6 inhibitors in the UK as they were included in this trial?

Coming back with more information after the presentation!”

“Imlunestrant with or without Abemaciclib in Advanced Breast Cancer”

Authors: Komal Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Lillian Smyth, François-Clément Bidard et al.

Olubukola Ayodele: The results of EMBER-3 are out in NEJM

Read the post “Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer” on oncodaily.com.

Dr. Olubukola Ayodele is a Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, specializing in breast and genitourinary malignancies, including germ cell tumors. She is also an honorary Senior Lecturer at the University of Leicester and heads the Breast Cancer Clinical Trials Unit at the Leicester Cancer Research Centre.

Dr. Ayodele’s work includes numerous publications, clinical trials, and collaborative research projects on molecular drivers and biomarkers in breast cancer. She is a member of ASCO, ESMO, ACP and UKBCG.]

Dr. Komal Jhaveri holds the Patricia and James Cayne Chair for Junior Faculty and serves as an Associate Member in the Breast Medicine Service and Early Drug Development at Memorial Sloan Kettering Cancer Center.

As Section Head of the Endocrine Therapy Research Program and Clinical Director of the Early Drug Development Service, Dr. Jhaveri focuses on innovative approaches for breast cancer treatment, particularly in early-phase clinical trials.